NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

13th Meet The Professor

Advanced International Breast Cancer Course (AIBCC)

Padua, September 21st - 23rd 2017



  • Slide Kit
  • Aims
  • Awards & Fellowships
  • Directors
  • Scientific Committee
  • Speakers & Chairmen
  • Program

The slides of the 2017 meeting are now available.

Click here

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.
With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.
This 13th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.
In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 13th AIBCC will award the 7th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.
We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-195749): 4,2 CME points.

The Meeting is addressed to physicians specialized in oncology, radiodiagnostics, radiotherapy, clinical pathology, general surgery, gynaecology and obstetrics; biologists and nurses. It will not be possible to give credits to physicians specialized in different fields.

The credit certification is subject to:

  • attendance at 90% of the Meeting
  • the completion of the Meeting evaluation form
  • the completion of the final questionnaire (at least 75% of correct answers)

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

 

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2017

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

CASE HISTORIES

Participants can send one or more case history to the scientific committee. The selected ones will be discussed during one of the three tumor boards (please see the program). People sending the selected case histories will have to present them and will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement 200,00 € for Italian participants and €300,00 for European participants). Case histories should be sent within July 31st. A confirmation will be sent by email within September 1st. For further details (such as time limit, number of slides to prepare and so on) please do not hesitate to send an email to This email address is being protected from spambots. You need JavaScript enabled to view it.

FELLOWSHIPS

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 1st. The organizing secretariat will confirm the award of the fellowship within July 20th and it will proceed with the organization of logistics.

UNDER 35

Free admission is available for 3 people "under 35". Registration forms will be accepted on a first-come, first-served basis until spaces will be full. The Organization Secretariat will confirm the registration by email.

Foto

Pier Franco Conte

Division of Medical Oncology 2

Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padua (I)

Foto

Gabriel N. Hortobagyi

Department of Breast Medical Oncology

The University of Texas - MD Anderson Cancer Center
Houston (USA)

Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Valentina Guarneri

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Jacek Jassem

Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl

German Breast Group
Department of Medicine and Research
University of Frankfurt (D)

Miguel Martin

Medical Oncology Service
Hospital Universitario Gregorio Marañon
Madrid (S)

Stefania Migliuolo

Europa Donna Italia
Milan (I)

Fedro Alessandro Peccatori

Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)

Philip Poortmans

President-elect of ESTRO
Department of Radiation Oncology
Radbound University Medical Centre
Nijmegen (NL)

Aleix Prat

Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Barcellona (E)

[Preliminary Faculty]

Enrica Baldan

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Francesco Bertolini
Department of Emato-Oncology
European Institute of Oncology
University of Milan (I)
Maria Joao Cardoso

Breast Unit
Fondation Champalimaud
Lisbon (P)

Giuseppe Curigliano

Department of Oncology
European Institute of Oncology
University of Milan (I)

Andrea De Censi

Medica and Preventive Oncology
E.O. Galliera Hospital
Genua (I)

Maia Dzhugashvili

Department of Radiation Oncology
Instituto Madrileño de Oncología (Grupo IMO)
Murcia (S)

Leticia De Mattos-Arruda

Institute of Oncology
Vall d’Hebron (VHIO)
Barcellona (S)

Maria Vittoria Dieci

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Marco Gambacciani

Obstetrics & Gynecology Unit
S. Chiara Hospital
Pisa (I)

Oreste Gentilini

Breast Unit
S. Raffaele Hospital
Milan (I)

Antonio Llombart-Cussac

Medical Oncology Service
University Hospital Arnau de Vilanova
Valencia (S)

Eleuterios Mamounas

Comprehensive Breast Program
MD Anderson Cancer Center
Orlando (USA)

Marco Montagna

Hereditary Tumors Group Breast and Ovary Cancer
Department of Oncological Molecular Diagnostic and Immunology
Istituto Oncologico Veneto
University of Padua (I)

Stefania Montemezzi

Department of Radiology
University Hospital
Verona (I)

Enrico Orvieto

General Pathology and Cythopatology Unit
Department of Medicine-DIMED
University of Padua (I)

Luigi Pescarini

Department of Radiology
Diagnostic Breast Unit
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Massimo Rugge

General Pathology & Cytopathology Unit
Department of Medicine-DIMED
University of Padua (I)

Hope Rugo

Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)

Peter Schmid

Centre for Experimental Cancer Medicine
Bart Cancer Institute
Queen Mary University
London (UK)

Giuseppe Viale

Department of Pathology
European Institute of Oncology
University of Milan (I)

Vincenzo Vindigni

Unit of Plastic and Reconstructive Surgery
University of Padua (I)

Thursday, September 21st

8.00

Registration

9.15

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi

SESSION I - LIFE STYLE AND BREAST CANCER

Chairmen: Gabriel N. Hortobagyi, Stefania Migliuolo

9.30

Body Mass Index: role as risk factor and predictor of endocrine therapy efficacy
Andrea De Censi

10.00

Hormone replacement therapy: the good and the bad
Marco Gambacciani

10.30

Breast cancer and pregnancy
Fedro Peccatori

11.00

Q&A

11.30

Coffee break

SESSION II - HIGH RISK WOMEN AND PERSONALISED SCREENING

Chairman: Andrea De Censi

11.45

Identification of high risk women: from family history to multigene panels
Marco Montagna

12.15

Personalized screening (including women with dense breasts or breast implants/augmentation)
Enrica Baldan

12.45

Q&A

13.10

Lunch

14.00

Multidisciplinary Tumor Board 1 – Management of women at high risk of breast cancer
Chairmen: Gabriel H. Hortobagyi, Luigi Pescarini

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Enrica Baldan, Maria Joao Cardoso, Andrea De Censi, Maia Dzhugashvili, Marco Gambacciani, Sibylle Loibl, Stefania Migliuolo, Marco Montagna, Stefania Montemezzi, Enrico Orvieto, Fedro Peccatori, Massimo Rugge

SESSION III - SURGERY & RADIOTHERAPY

Chairmen: Jacek Jassem, Elefterios Mamounas

15.00

Management of in situ carcinoma: state of art
Maria Joao Cardoso

15.30

Sentinel node biopsy: when should be spared?
Oreste Gentilini

15.50

Sentinel node biopsy: before or after NACT?
Elefterios Mamounas

16.10

Lipofilling: are preclinical data fully reassuring?
Francesco Bertolini

16.30

Lipofilling after breast cancer: the surgeon’s point of view
Vincenzo Vindigni

16.50

Radiation therapy: when more is better and when less is good
Philip Poortmans

17.20

Q&A

17.30

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2017

18.00

Lecture of the Awardee

18.30

Cocktail

20.00

Adjourn

Friday, September 22nd

SESSION IV - PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

Chairmen: Aleix Prat, Massimo Rugge

9.00

Baseline assessment: new AJCC classification
Gabriel N. Hortobagyi

9.30

HER2 testing guidelines for the clinicians: equivocal means yes or no?
Giuseppe Viale

10.00

Genomic tests: clinical utility after TailoRx and Mindact
Maria Vittoria Dieci

10.30

Liquid biopsy (ctDNA, CTC, miRNA): ready for clinical use?
Leticia de Mattos-Arruda

11.00

Q&A

11.15

Coffee break

11.30

SESSION V – ACTIONABLE PATHWAYS IN BREAST CANCER SUBTYPES

Chairmen: Pierfranco Conte, Sibylle Loibl

11.45

Luminal tumors and endocrine resistance
Stephen Johnston

12.15

Targeting the immune system: TN and beyond
Peter Schmid

12.45

HER2+ and trastuzumab resistance
Aleix Prat

13.15

Q&A

13.30

Lunch

14.30

Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (including CUP syndrome, breast cancer during pregnancy)
Chairman: Pierfranco Conte

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Maria Joao Cardoso, Hesham A. Gaballah Elghazaly, Gabriel N Hortobagyi, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Elefterios Mamounas, Miguel Martin, Stefania Migliuolo, Fedro Peccatori, Philip Poortmans, Aleix Prat, Massimo Rugge, Giuseppe Viale

16.00

Coffee break

SESSION VI – ADJUVANT TREATMENTS

Chairmen: Gabriel N. Hortobagyi, Stephen Johnston

16.20

HR+ disease:
when more is better – Hope Rugo
when less is good – Giuseppe Curigliano

17.00

HER2+ disease:
when more is better – Antonio Llombart-Cussac
when less is good – Pier Franco Conte

17.40

Triple Negative:
when more is better – Valentina Guarneri
when less is good – Miguel Martin

18.20

Q&A

18.30

Adjourn

Saturday, September 23rd

SESSION VIII – ABC PATIENTS

Chairmen: Hesham A. Gaballah Elghazaly, Valentina Guarneri

9.00

New therapeutic algorithms
HR+ ABC – Stephen Johnston
HER2+ ABC – Sibylle Loibl
TN ABC – Hope Rugo

10.30

Q&A

10.45

Highlights from major meeting (ASCO, ESMO, SABCS, ST GALLEN)
Jassem Jacek

11.15

Coffee break

11.45

Multidisciplinary Tumor Board 3 – Management of advanced breast cancer
Chairmen: Pierfranco Conte, Miguel Martin

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncologists, pathologists, radiologists, radiation oncologists, surgeons and representatives of advocacy group will comment the votes and express their opinions.

Participants: Pier Franco Conte, Giuseppe Curigliano, Hesham A. Gaballah Elghazaly, Valentina Guarneri, Jacek Jassem, Gabriel n. Hortobagyi, Stephen Johnston, Sibylle Loibl, Stefania Migliuolo, Fedro A. Peccatori, Philip Poortmans, Aleix Prat, Hope Rugo

13.15

Adjourn and final evaluation questionnaire

Meeting Venue

Palazzo del Bo, Via VIII Febbraio 2, Padova.
+39.049.803.37.11

 

How to reach the meeting venue